EUVIMEDEUVIMED entdecken
Open Access

Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons

Dhruv Gohel, Pengyue Zhang, Amit Kumar Gupta, Yichen Li, Chien-Wei Chiang, Lang Li, Yuan Hou, Andrew A Pieper, Jeffrey Cummings, Feixiong Cheng

Journal of Alzheimer’s Disease · 19.03.2024 · 98 (2) · 643-657

DOI: 10.3233/jad-231391 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2024-03. Verfasst von Dhruv Gohel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Genomic Medicine Institute,Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Induced Pluripotent Stem Cells, Neurodegenerative Diseases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NINDS NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alzheimer’s disease (AD) is a chronic neurodegenerative disease needing effective therapeutics urgently. Sildenafil, one of the approved phosphodiesterase-5 inhibitors, has been implicated as having potential effect in AD.

Objective

To investigate the potential therapeutic benefit of sildenafil on AD.

Methods

We performed real-world patient data analysis using the MarketScan ® Medicare Supplemental and the Clinformatics ® databases. We conducted propensity score-stratified analyses after adjusting confounding factors (i.e., sex, age, race, and comorbidities). We used both familial and sporadic AD patient induced pluripotent stem cells (iPSC) derived neurons to evaluate the sildenafil’s mechanism-of-action.

Results

We showed that sildenafil usage is associated with reduced likelihood of AD across four new drug compactor cohorts, including bumetanide, furosemide, spironolactone, and nifedipine. For instance, sildenafil usage is associated with a 54% reduced incidence of AD in MarketScan ® (hazard ratio [HR] = 0.46, 95% CI 0.32– 0.66) and a 30% reduced prevalence of AD in Clinformatics ® (HR = 0.70, 95% CI 0.49– 1.00) compared to spironolactone. We found that sildenafil treatment reduced tau hyperphosphorylation (pTau181 and pTau205) in a dose-dependent manner in both familial and sporadic AD patient iPSC-derived neurons. RNA-sequencing data analysis of sildenafil-treated AD patient iPSC-derived neurons reveals that sildenafil specifically target AD related genes and pathobiological pathways, mechanistically supporting the beneficial effect of sildenafil in AD.

Conclusions

These real-world patient data validation and mechanistic observations from patient iPSC-derived neurons further suggested that sildenafil is a potential repurposable drug for AD. Yet, randomized clinical trials are warranted to validate the causal treatment effects of sildenafil in AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseInduced Pluripotent Stem CellsNeurodegenerative DiseasesAgedUnited StatesHumansSildenafil CitrateSpironolactonetau ProteinsMedicareNeurons

Stichwörter der Autor:innen

KeywordsAlzheimer’s diseaseRNA-sequencinginduced pluripotent stem cellsphosphodiesterase-5 (PDE5)real-world patient datasildenafiltau phosphorylation

Substanzen

Sildenafil CitrateSpironolactonetau Proteins

Autor:innen und Institutionen

  • Genomic Medicine Institute,Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
  • Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN, USA.
  • Department of Biomedical Informatics, College of Medicine, Ohio State University, Columbus, OH, USA.
  • Brain Health Medicines Center, Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.
  • Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA.
  • Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center, Cleveland, OH, USA.

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • NIGMS NIH HHS
  • BLRD VA

Zitieren

APA

Gohel, D., Zhang, P., Gupta, A. K., Li, Y., Chiang, C. W., Li, L., Hou, Y., Pieper, A. A., Cummings, J., & Cheng, F. (2024). Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons. Journal of Alzheimer’s Disease, 98(2), 643-657. https://doi.org/10.3233/jad-231391

Vancouver

Gohel D, Zhang P, Gupta AK, Li Y, Chiang CW, Li L, et al. Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons. Journal of Alzheimer’s Disease. 2024;98(2):643-657. doi:10.3233/jad-231391

BibTeX
@article{Gohel2024,
  author = {Gohel, Dhruv and Zhang, Pengyue and Gupta, Amit Kumar and Li, Yichen and Chiang, Chien-Wei and Li, Lang and Hou, Yuan and Pieper, Andrew A and Cummings, Jeffrey and Cheng, Feixiong},
  title = {Sildenafil as a Candidate Drug for Alzheimer’s Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons},
  journal = {Journal of Alzheimer’s Disease},
  year = {2024},
  volume = {98},
  number = {2},
  pages = {643--657},
  doi = {10.3233/jad-231391}
}
Kostenlos starten →